Pacira BioSciences, Inc. PCRX Net product sales — Total net product sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s net product sales — total net product sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s net product sales — total net product sales?
- Pacira BioSciences, Inc. (PCRX) reported net product sales — total net product sales of $177.38M in Q1 2026.
- How has Pacira BioSciences, Inc.'s net product sales — total net product sales changed year-over-year?
- Pacira BioSciences, Inc.'s net product sales — total net product sales increased by 5.8% year-over-year, from $167.59M to $177.38M.
- What is the long-term trend for Pacira BioSciences, Inc.'s net product sales — total net product sales?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s net product sales — total net product sales has grown at a 7.6% compound annual growth rate (CAGR), from $538.97M to $722.85M.
- What does net product sales — total net product sales mean?
- This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of the company's commercial success and market adoption of its core product portfolio. Investors use this figure to evaluate the underlying demand for the company's therapeutic offerings independent of other revenue streams.